upgrad ow much upsid potenti
ignor
bullish baxter head share come realli
strong see major disconnect baxter deliv
street model sale street ep
street forecast organ sale growth
ex-cyclo headwind ep vs street
believ baxter offer upsid potenti number
within large-cap med-tech upgrad ow rais
ye price target valu baxter ev/ebitda
ep vs peer assum baxter trade par peer
ev/ebitda view appropri given lower leverag
level vs peer modest premium ep
baxter turnaround stori play better expect think
still plenti room go sinc take januari ceo
almeida transform compani low-margin low-fcf busi one
that significantli under-lev gener signific vs
expand oper margin two
year baxter today top-lin growth busi see upsid potenti
opportun achiev margin expans next
year driven mix upgrad gross margin improv exist
busi control oper spend that without put work
underleverag balanc sheet net debt could use drive
earn power either accret larg share buyback
neither seem reflect street model
multipl busi segment forecast upsid vs street
biggest disconnect us iv solut
market recent year becom increasingli suppli constrain situat
made wors braun may fda warn letter subsequ
manufactur challeng well disrupt hurrican maria
start jan baxter approv import volum mexico iv
facil satisfi us demand baxter begin ship unit
effect us market us mexico volum
previous allot mexican tender renew
page analyst certif import disclosur
 morgan seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report singl
factor make invest decis
repres increment opportun baxter
alon could add sale growth importantli would profit
us estim baxter abl charg per unit vs
previous get mexican tender net benefit
unit street appear model impact shift volum
forecast us fluid system sale
street assum benefit new contract plu easi comp
impact lost hurricane-rel sale intern
street assum sale growth off-set
lost tender sale
second sourc potenti upsid vs street renal renal grew
exclud low- no-margin
busi baxter walk away start growth
see growth pd growth crrt
stabil renal therapi servic vs tough comp ex-
discontinu busi
street seem miss renal turnaround in-cent
hemodialysi busi predominantli legaci gambro busi
struggl past year price eros competit particularli ou
price cut annual dialyz manufactur baxter
launch cost-effect product better compet addit monitor sale
stabil ad in-cent turnaround growth
first time posit sinc follow growth
growth forecast in-cent hd
growth growth continu
final see upsid integr pharmaci solut ip eas
comp ip sale broken three categori base busi
us cyclophosphamid sale slowli go gener clari
busi baxter acquir juli forecast us base busi sale
due neg impact hurrican report
us base busi growth intern base busi grow
includ tough comp due settlement forecast
us cyclo busi gener assum
eros quarter clari busi grow overal
impact rather small sale
cant say sure sens ip street properli
model contribut clari assum
substanti cyclo degrad factor lost us sale
hurrican factor neg impact
voluntarili discontinu busi neg impact fewer
sell day like combin item regardless think street
under-model ip head
beyond forecast conserv call organ revenu growth
ep growth assum ebita margin improv
ebitda margin improv
improv share buyback proxi capit deploy
acquisit add underli growth though come show
baxter net cash posit suggest meaning upsid potenti
model addit capit deploy
baxter zero net debt leav compani edward intuit
surgic three large-cap med-tech compani havent deploy
balanc sheet averag large-cap med-tech compani net
debt/ebitda vs baxter zero net debt repres compani
ev ceo almeida publicli open market cap
approach capit alloc like balanc
combin capit return goal grow earn
upgrad baxter mix busi sustain growth rate compani
find right target execut transact deliv
synergi lot work attempt improv product
profit cultur exist busi expect manag
disciplin select right deal announc combin share
buyback
final worth touch tax reform impact baxter
rel neutral get updat morgan healthcar
confer next week read baxter current tax rate ex-stock
option account shouldnt move much though short run could uptick
littl baxter us tax base proport smaller sale base much
debt resid us mean lower statutori rate wouldnt signific
impact anti-bas eros neg impact compani ou tax
rate move slightli higher moreov new tax law includ limit interest
deduct neg larg off-set benefit shift
territori system point net impact baxter unknown even
assum increas effect rate estim impact would
amount forecast could easili absorb
upgrad baxter ow rais ye price target
valu baxter ev/ebitda ep
compar large-cap med-tech peer ev/ebitda
ep assum baxter trade par peer ev/ebitda
appropri view given lower leverag vs peer modest premium
ep
invest thesi valuat risk
bullish baxter head share come realli
strong see major disconnect baxter deliv
street model sale street
ep street forecast organ sale
growth ex-cyclo headwind ep vs street
believ baxter offer upsid potenti number
within large-cap med-tech upgrad ow rais
ye price target
baxter turnaround stori play better expect think there
still plenti room go sinc take januari ceo almeida
transform compani low-margin low-fcf busi one that
significantli under-lev gener signific vs
expand oper margin two year
baxter today top-lin growth busi see upsid potenti
opportun achiev margin expans next year
driven mix upgrad gross margin improv exist busi
control oper spend that without put work underleverag
balanc sheet debt use drive earn power
either accret larg share buyback neither seem
reflect street model
dec price target valu baxter equal blend
ev/ebitda ep compar large-cap med-tech peer
ev/ebitda ep assum baxter trade par
peer ev/ebitda appropri given lower leverag level vs
peer modest premium ep due potenti upsid capit
risk rate price
downsid risk includ manag inabl deliv margin
expans target misalloc balanc sheet potenti
reimburs price cut
baxter summari financi
cash equival
flow oper activ
o/w chang work capit
flow invest activ
sale
flow financ activ
net chang cash
adj free cash flow firm
compani report morgan estim
note million except per-shar data fiscal year end dec o/w
analyst certif research analyst denot ac cover report certifi multipl research
analyst primarili respons report research analyst denot ac cover within document
individu certifi respect secur issuer research analyst cover research view
express report accur reflect person view subject secur issuer part
research analyst compens directli indirectli relat specif recommend view
express research analyst report korea-bas research analyst list front cover also certifi per
kofia requir analysi made good faith view reflect opinion without undu influenc
